Van Montfrans Joris M, Hartman Esther A R, Braun Kees P J, Hennekam Eric A M, Hak Elisabeth A, Nederkoorn Paul J, Westendorp Willeke F, Bredius Robbert G M, Kollen Wouter J W, Schölvinck Elisabeth H, Legger G Elizabeth, Meyts Isabelle, Liston Adrian, Lichtenbelt Klaske D, Giltay Jacques C, Van Haaften Gijs, De Vries Simons Gaby M, Leavis Helen, Sanders Cornelis J G, Bierings Marc B, Nierkens Stefan, Van Gijn Marielle E
Department of Pediatric Immunology and Infectious Diseases,
Department of Pediatric Immunology and Infectious Diseases.
Rheumatology (Oxford). 2016 May;55(5):902-10. doi: 10.1093/rheumatology/kev439. Epub 2016 Feb 10.
To determine the genotype-phenotype association in patients with adenosine deaminase-2 (ADA2) deficiency due to identical homozygous R169Q mutations inCECR1 METHODS: We present a case series of nine ADA2-deficient patients with an identical homozygous R169Q mutation. Clinical and diagnostic data were collected and available MRI studies were reviewed. We performed genealogy and haplotype analyses and measured serum ADA2 activity. ADA2 activity values were correlated to clinical symptoms.
Age of presentation differed widely between the nine presented patients (range: 0 months to 8 years). The main clinical manifestations were (hepato)splenomegaly (8/9), skin involvement (8/9) and neurological involvement (8/9, of whom 6 encountered stroke). Considerable variation was seen in type, frequency and intensity of other symptoms, which included aplastic anaemia, acute myeloid leukaemia and cutaneous ulcers. Common laboratory abnormalities included cytopenias and hypogammaglobulinaemia. ADA2 enzyme activity in patients was significantly decreased compared with healthy controls. ADA2 activity levels tended to be lower in patients with stroke compared with patients without stroke. Genealogical studies did not identify a common ancestor; however, based on allele frequency, a North-West European founder effect can be noted. Three patients underwent haematopoietic cell transplantation, after which ADA2 activity was restored and clinical symptoms resolved.
This case series revealed large phenotypic variability in patients with ADA2 deficiency though they were homozygous for the same R169Q mutation inCECR1 Disease modifiers, including epigenetic and environmental factors, thus seem important in determining the phenotype. Furthermore, haematopoietic cell transplantation appears promising for those patients with a severe clinical phenotype.
确定由于 CECR1 基因中相同的纯合 R169Q 突变导致腺苷脱氨酶 2(ADA2)缺乏患者的基因型 - 表型关联。
我们报告了一组 9 例具有相同纯合 R169Q 突变的 ADA2 缺乏患者。收集了临床和诊断数据,并回顾了现有的 MRI 研究。我们进行了系谱和单倍型分析,并测量了血清 ADA2 活性。将 ADA2 活性值与临床症状相关联。
9 例患者的发病年龄差异很大(范围:0 个月至 8 岁)。主要临床表现为(肝)脾肿大(8/9)、皮肤受累(8/9)和神经受累(8/9,其中 6 例发生中风)。其他症状的类型、频率和强度存在相当大的差异,包括再生障碍性贫血、急性髓系白血病和皮肤溃疡。常见的实验室异常包括血细胞减少和低丙种球蛋白血症。与健康对照相比,患者的 ADA2 酶活性显著降低。与未发生中风的患者相比,发生中风的患者 ADA2 活性水平往往较低。系谱研究未发现共同祖先;然而,基于等位基因频率,可以注意到西北欧奠基者效应。3 例患者接受了造血细胞移植,移植后 ADA2 活性恢复,临床症状缓解。
该病例系列显示,尽管 CECR1 基因中相同的 R169Q 突变呈纯合状态,但 ADA2 缺乏患者的表型变异很大。因此,包括表观遗传和环境因素在内的疾病修饰因子在决定表型方面似乎很重要。此外,造血细胞移植对于那些具有严重临床表型的患者似乎很有前景。